Home | Business News | Browse by Publication | P | Pharma Marketletter

Amgen's Kepivance cleared by EC.

Publication: Pharma Marketletter
Publication Date: 07-NOV-05
Format: Online
Delivery: Immediate Online Access
Full Article Title: Amgen's Kepivance cleared by EC.(European Union)(Brief Article)

Article Excerpt
USA-based biotechnology giant Amgen's Kepivance (palifermin) has received regulatory approval in the European Union as a treatment for mucositis (mouth sores) in patients with hematologic cancers undergoing myeloablative therapy associated with a high incidence of severe oral mucositis, and requiring autologous blood and bone marrow transplant.

Willard Dere, Amgen's...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Pharma Marketletter
Japan stock market week to Oct 31., November 07, 2005
AstraZeneca posts whopping 52% 3rd-qtr EPS rise but disappoints invest..., November 07, 2005
GlaxoSmithKline pleases with 3rd-qtr results and raised full-year guid..., November 07, 2005
Dr Reddy's profit up 72%, despite US pressures.(Brief Article), November 07, 2005
Ranbaxy to invest $59M in new SEZ.(pharmaceutical special economic zon..., November 07, 2005

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.